MyProstateScore 2.0 (MPS2) offers physicians and patients the most comprehensive and flexible prostate cancer risk assessment tool. I am a Provider I am a Patient MYPROSTATESCORE 2.0 Clear Results. Confident Decision. MPS2 is a urine test designed to predict the presence of clinically significant...
Cooperberg MR: Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer 2008, 113: 3062–3066.Cooperberg MR. Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer 2008;113:3062-6.Cooperberg MR. Prostate cancer risk assessment: choosing the ...
"The population has changed. The risk factors have changed," said Ian M. Thompson Jr., MD, director of the Cancer Therapy and Research Center at the University of Texas Health Science Center in San Antonio, who was instrumental in developing the first version of the calculator. "The general...
The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis. 2006;9(... C Kastner,J Armitage,...
[1]. In contrast, oncemetastasishas been detected by imaging, the vast majority of patients will likely die from prostate cancer. Over the past two decades, serum PSA screening has provided a valuable tool for prostatecancer surveillance, however the age-adjusted incidence of mortality has ...
To improve preoperative risk stratification for prostate cancer (PCa) by incorporating multiparametric MRI (mpMRI) features into risk stratification tools
Conclusions:The PCCI is a claims based, externally validated tool to predict mortality in men with prostate cancer. Integrating the PCCI into clinical pathways may improve prostate cancer management through more accurate assessment of life expectancy. 展开 ...
The choice of instrument may vary depending on whether the clinician intends to use it for screening symptoms or clinical research, and with which identifiable complaints the patient presents, e.g., the Functional Assessment of Cancer Therapy (FACT)-Cognitive tool explores different domains than the...
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic
Prostate cancer is a leading cause of morbidity and mortality for adult males in the US. The diagnosis of prostate carcinoma is usually made on prostate core needle biopsies obtained through a transrectal approach. These biopsies may account for a signif